The FDA classified a thyroid medicine recall by Vitruvias Therapeutics as Class I, its highest risk level, on September 22. One lot of 30 mg thyroid tablets distributed nationwide from January to September 2025 was recalled because testing confirmed they could be superpotent, potentially causing serious health effects like overactive thyroid, weight loss, and hypertension.